[1] Besheer T, Arafa M, El-Maksoud MA, et al. Diagnosis of cirrhosis in patients with chronic hepatitis C genotype 4: Role of ABCB11 genotype polymorphism and plasma bile acid levels. TurkJ Gastroenterol, 2018, 29(3):299-307. [2] 杨才勇, 陈娜, 李奎, 等. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨. 实用肝脏病杂志, 2019, 22(6):868-871. [3] Rashad NM, El-Shal AS, Shalaby SM, et al. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma. Mol Cell Biochem, 2018, 47(1-2):125-136. [4] Weis A, Marquart L, Calvopina DA, et al. Serum microRNAs as biomarkers in hepatitis C: Preliminary evidence of a microRNA panel for the diagnosis of hepatocellular carcinoma. Int J Mol Sci, 2019, 20(4):864. [5] 林升龙, 王香梅, 马华晳, 等. 基于芯片和公共数据库数据分析微RNA在乙型肝炎病毒感染中的可能机制. 中华传染病杂志, 2020, 38(11):717-722. [6] Nan Y, Niu X, Wang R, et al. microRNA-1273g-3p is a useful non-invasive test for the prediction of liver fibrosis in patients with chronic hepatitis C. Exp Ther Med, 2019, 17(3):1817-1824. [7] 纪冬, 游绍丽, 辛绍杰. 《丙型肝炎防治指南(2015年更新版)》要点解读. 传染病信息, 2016, 29(1):20-23. [8] 徐小元, 丁惠国, 李文刚, 等. 肝硬化诊治指南. 实用肝脏病杂志, 2019, 22(6):18-34. [9] Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm. World J Gastroenterol, 2019, 25(29):3929-3940. [10] Hwang JP, LoConte NK, Rice JP, et al. Oncologic implications of chronic hepatitis C virus infection. J Oncol Pract, 2019, 15(12):629-637. [11] Hedenstierna M, Nangarhari A, El-Sabini A, et al. Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C. J Viral Hepat, 2018, 25(7):802-810. [12] Lowey B, Hertz L, Chiu S, et al. Hepatitis C virus infection induces hepatic expression of NF-κB-inducing kinase and lipogenesis by downregulating miR-122. mBio, 2019, 10(4):e01617-619. [13] Santangelo L, Bordoni V, Montaldo C, et al. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver Int, 2018, 38(10):1741-1750. [14] Horii R, Honda M, Shirasaki T, et al. MicroRNA-10a impairs liver metabolism in hepatitis C virus-related cirrhosis through deregulation of the circadian clock gene brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1. Hepatol Commun, 2019, 3(12):1687-1703. [15] Mohamed AA, Omar AAA, El-Awady RR, et al. MiR-155 and MiR-665 role as potential non-invasive biomarkers for hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. J Transl Int Med, 2020, 8(1):32-40. [16] El-Hefny M, Fouad S, Hussein T, et al. Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients. J Med Virol, 2019, 91(1):93-101. [17] Lendvai G, Szekerczés T, Gyöngyösi B, et al. MicroRNA expression in focal nodular hyperplasia in comparison with cirrhosis and hepatocellular carcinoma. Pathol Oncol Res, 2019, 25(3):1103-1109. [18] Hassan AS, Elgendy NA, Tawfik NA, et al. Serum miR-483-5p and miR-133a as biomarkers for diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients. Egypt J Immunol, 2019, 26(2):31-40. [19] Liu B, Yang XF, Liang XP, et al. Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 2018, 22(23):8431-8437. [20] Nasser MZ, Zayed NA, Mohamed AM, et al. Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. Arab J Gastroenterol, 2019, 20(4):198-204. |